¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º $~2A o[  
9#agI|d~  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ <ImeZ'L7  
>s>5k O  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ql zL<  
E^qKkl  
1. ICAM-1 6yR7RF}  
VP"L _Um  
2. interleukin 12(IL-12) ;xRy ONt  
?LW1D+  
3. tumor infiltrating lymphocyte \ pq]q  
fGxa~Unx  
4. TCR/CD3 complex b :+ X3  
=]"PSY7p  
5. hematopoietin receptor family L2:C6Sc  
9:m+mpL=9  
6. individual idiotype(IdI) |_A35"v  
-}>Q0d)  
7. integrin 4f>Vg$4  
,JjTz O  
8. colony-stimulatory factor (CSF) y K{~  
D4S>Pkv  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ;TR.UUT  
+[>m`XTq  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? 5zU D W?  
18`?t_8g  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ *AJW8tIP  
4A*' 0!H  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠNc7YMxk'H  
Aw5yvQ>]e  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ h  qxe  
ptsi\ 7BG  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) m*(8I=]q  
Vdjca:`  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ rSa 3u *xB  
BO1Mz=q  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) {!<zk+h$  
~UL; O\-b0  
3. immunoglobulin superfamily (IgSF) =XqmFr;h  
x&kF;UC  
4. selectin BK-{z).)  
U/TF,JUI  
5. anti-idiotypic antibody (¦ÁId) |{Oe&j3|  
6 s*#y [$  
6. major histocompatibility complex(MHC) C7nLa@  
g4U%(3,>D  
7. immunotolerance |J8c|h<  
RU@`+6 j+  
8. biological reponse modifier(BRM) 1YQ|KJ*K  
t.3b\RV[  
9. immune reponse gene (Ir gene) $_NVy>\&  
-MeGJX:^I  
10. reshaped antibody (or reconstituted antibody) HD$W\P  
>+&524xc  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© '(~+ \  
  Lxs  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ oS, %L  
4OC ^IS  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? L_Ff*   
+H8]5~',L%  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ l7nc8K  
zcy!Y B  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? QT&2&#Z  
up#W"`"  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ DFcgUEq  
X6kCYTJYF  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? j!F5gP-l  
Ho2#'lSKM  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 3)3?/y)_  
> ;LXy  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ iP)`yB5`  
j KGfm9|zj  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? *2P%731n5  
3MH9%*w'0  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ !{>'jvH  
V:s$V.{!  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: JZ3CCf  
@y ] ek/  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: #ue WU  
XYj!nx{k,  
ÃâÒßѧ _3~/Z{z8  
KPHtD4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© |qm_ESzl  
ZRHK?wg'#  
1. CD8 fqpbsM;M]  
!LJEo>D  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) ,Pi!%an w  
S#Q 0aG j  
3. immunoglobulin fold(Ig fold) Is&0h|  
Rxb?SBa  
4. cadherin (Ca-dependent cell adhesion moleculers) SbLm  
5ir Ffr  
5. idiotype-anti-idiotypic antibody immune network theory w2X0.2)P2  
2i0 .x  
6. HLA class II antigen )+7|_7 !x  
F+@/"1c  
7. complementarity-determining region (CDR) *Ri\7CqU"6  
I%(YR"  
8. perforin(or pore-forming protein ,PFP) amTeT o]Tg  
j)nL!":O  
9. high affinity IL-2 receptor ,ArHS  
Nwwn #+  
10. artificial active immunization I4XnJ[N%  
M}fk[Yr>  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© PfR|\{(  
g ?.y7!m  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ^%n]_[RUn4  
YjCHKI"e  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ='vD4}"j  
gU&y5s~  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ oyT`AYa  
]4ib^R~Z  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ H@xHkqan  
dAWB.#  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ G{.[o6>  
jj&mRF0gCb  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? u\{MQB{T  
"4IrW6B $9  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ^sKdN-{  
8NkyT_\  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ iE EP~  
#iKPp0`K*  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 9^u}~e #(  
/a*8z,x  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ~GE|,Np  
4bCA"QM[[  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ) &DsRA7v  
;Fo7 -kK  
1. immunoglobulin gene rearrangement  Q 'ZZQ  
?)ct@,Ek$  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) IgjPy5k  
E-%$1=;  
3. flow cytometry(FCM) q*Oj5;  
Y<IuwS  
4. carrier effect \2!.  
*8Su:=*b  
5. positive selection of T lymphocytes in thymus F Uz1P  
T X iu/g(  
6. mouse TH1(Th1) and TH2(Th2) subsets }3, 4B -8!  
k.7!)jL7  
7. perforin (pore-forming protein ,PFP) <"K2t Tg.  
_M&n~ r  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) lI%RdA[  
BL~#-Mm<|l  
9. SH-2(src-homology region 2) _k : BY  
ePZ Ai"k  
10. Ab2¦Â (internal image) Y}xM&%  
E=8GSl/Jx  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© @{U UB=}9  
JhjH_)  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? :{^~&jgL  
t*; KxQ+'?  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? QgKR=GR6  
BQ<\[H;  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠJU;`c>8=)  
]%I\FefT  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ FZ}^)u}o  
`mW~{)x  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠj!kJ@ lbP  
:/%Y"0  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) 2@?X>,  
tBfmjxv  
ÃâÒßѧרҵ£º Z m%,L$F*L  
C-)d@LWI  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ M%la@2SK=  
Ywv\9KL  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? )A%* l9\nG  
TQKcPVlE  
´«È¾²¡Ñ§×¨Òµ£º  * U6+b  
,?Ie!r$6  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ wkPjMmW+!  
CshME\ /  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ra6\+M~}e  
,52Lm=n  
Ïû»¯×¨Òµ£º  oJ* ,a  
gE $Uv*Gj  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ +6l#hO7h  
t:V._@  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? vf@j d}?  
N>YSXh`W`y  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ J5F@<vi  
Lfcy#3!  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 3M+rFB}tS  
X EbVsw  
1. Fas(CD95)/FasL %XeN_ V  
{4A,&pR  
2. common chain of cytokine receptor LQr!0p.i"  
&y1iLk h^  
3 . TCR/CD3 complex yA"?Hv\o;  
`Mt|+iT$p  
4. negaive selection of thymocytes P (7Q8i '  
r5UV BV8T  
5. artificial active immune %z1^  
Q|{b8K  
6. anti-idiotypic - E GZ  
m F~]P8  
7. IgSF u 6?9#L(  
`?R{sNr.  
8. Integrin '" %0UflJS  
R_g(6l"3R^  
9. chemokine BF2U$-k4  
o!~XYEXvUa  
10. B7/CD28 R31Z(vY  
{ V(~  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© +aEm]=3  
j7Y7&x"  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ k Qr  
s#aj5_G  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ BQ u8$W  
4.wrY6+V  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ M[z1B!rT  
XI[n!)3  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ cMT:Ij];  
e~(e&4pb  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ p.8  
c-(dm:  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ # }}6JM  
 s:xJ }Ll  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© tK e-Dk9  
zb4@U=?w}  
1. B7/CD28 Wp:vz']V  
Da8gOZ  
2. Th1 subset ]R}(CaT1  
T+B-R\@t  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ]9w8[T:O  
zGz}.-F  
4. antibody affinity maturation PknKzrEG:>  
%f("3!#H  
5. AP-1 ']\SX*z?  
fDW:|%{Y,  
6. single chain variable fragment£¨ScFv£© k\SqDmv  
:5j+^/   
7. NK cell receptor n^|xp;] :  
)nj fqg  
8. Zinkernagel-Doherty phenomenon l"`VvW[  
@VIY=qh  
9. Ig fold t@MUNW`Q  
C%E~9_w  
10. CD40/CD40L j<BRaT  
y*sVimx  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© i={4rZOD^  
D8~\*0->  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 1c]{rO=taN  
DQ/rx`BG  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ J> ,w},`  
[ypE[   
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ W vu 1?  
t$VRNZ`dy  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ gq*W 0S  
)OFN0'  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£  HRbv%  
[hot,\+f  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ OIw[sum2  
*5s*-^'#!  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ Fz<1xyc(  
1~E4]Ef:W  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© dZ* &3.#D5  
bxL'k/Y$  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© .L1[Rv3  
bYem0hzOe  
1.Co-stimulators (or co-stimulating molecules) OKau3T]  
+.^pAz U}R  
2.NK-kB ~~"U[G1  
ABp8PD  
3.Immunoglobulin superfamily rbv  
ir\)Hz2P  
4.antigen-presenting cell (APC) %1GKN|7  
G eB-4img  
5.death domain ,SdxIhL  
,d.5K*?aI  
6.CCR and CXCR {`)o xzR  
'ju_l)(R  
7.Lectin (or mitogen) +5R8mbD!  
fh1-]$z`~  
8.Clusters of differentiation, CD) As^eL/m2L  
B2_fCSlg  
9.B7 family ]JmE(Y1(1  
Q=[ IO,f  
10.Cytotoxic T lymphocyte, CTL) r~,3  
-<T> paE9  
11.IL-15 and IL-15 receptor (IL-15R) &FZ~n?;hQ  
,PKUgL}w  
12.MHC restriction &i`(y>\  
_|MK0'+f  
13.Affinity-chromatography M[iWWCX  
+zo\#8*0MF  
14.Cyctosprin A, CsA Yyw3+3  
C4-%|+Q i  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) q!5`9u6  
28}L.>5k  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© {Ov{O,c 5  
(Nf!E[ }Z  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 %(\et%[]  
R"F:(  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ Vm I Afe  
3Dj>U*fP  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ _4k zlD  
 00Ye ]j_  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© uSxldc  
N{Pa&/V  
ÃâÒßѧרҵ£º zrC1/%T  
/|v b)J  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ `w "ooK  
 N=!k2+  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ `yRt?UQRS  
]0}NF  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ Qg o| \=  
H]{`q  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) k/Ao?R=@gI  
uUv^]B 8GM  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) ORIXcj]  
G98fBw  
1. ADCC(antibody dependent cell-mediated cytotoxicity) ^/$U(4  
07,&weQ  
2. »·æß¾úËØ(cyclosporin) T&E'MB  
#<-%%  
3. KIR(killer cell inhibitory receptor) 0 \o5+  
_=I&zUF  
4. HLDA(human leucocyte differentiation antigen) [ofZ1hB4  
*!}bU`  
5. Interleukin 18(IL-18) [XNDYaF8  
i%r+/D)KvG  
6. ÕûºÏËØ(integrin) 7{OD/*|  
)=#zMdK&  
7. Fas/FasL -JdNA2P  
2)|G%f_lS  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) !<0 `c  
A4TW`g_zm  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) .JWN\\  
,Y0qGsV  
10. Th1/Th2 *XG.?%x*|  
7hKfxw-X@  
11. »ùÒòÒßÃç(DNAÒßÃç) di~ [Ivw  
]P4? jKI  
12. chemokines and chemokine receptor 7$J E+gL/7  
.oe\wJS6  
13. ÃâÒßÄÍÊÜ tAS[T9B  
%u*HNo  
14. ¹²´Ì¼¤·Ö×Ó slG%o5|m  
UH7FIM7kX  
15. ËÀÍö½á¹¹Óò(death domain) 81S0:=   
)bB Va^  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) n wO5<b;  
3^Z@fC  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? Ev1gzHd!i  
VJ-To}  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠbMN ]co  
9_J'P2e  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î X;yThb` iI  
lxtt+R  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ O|0,= 5  
Qa,$_ ,E  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå 0Q:l,\lY  
Q^Q6| n  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ $&. rS.*  
(6X{ &  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) $%?[f;S3,  
ic?(`6N8  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ L [X "N  
88A,ll%  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ opon "{  
d(9C7GLC,  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»